MedPath

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.

Phase 1
Completed
Conditions
Clostridium Difficile Infection
Interventions
Other: Placebo
First Posted Date
2014-04-08
Last Posted Date
2016-06-13
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
36
Registration Number
NCT02106338
Locations
🇺🇸

Quintiles Phase I Services - Overland Park, Overland Park, Kansas, United States

Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome

Phase 2
Conditions
Hypereosinophilic Syndrome
Interventions
First Posted Date
2014-04-02
Last Posted Date
2017-12-07
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
15
Registration Number
NCT02101138
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations

Phase 2
Completed
Conditions
Influenza
Interventions
Biological: Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203
First Posted Date
2014-04-01
Last Posted Date
2017-07-06
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
270
Registration Number
NCT02100436
Locations
🇺🇸

University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States

🇺🇸

Emory Children's Center - Pediatric Infectious Diseases, Atlanta, Georgia, United States

🇺🇸

Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States

and more 5 locations

Impact of TMP-SMX Prophylaxis on Malaria Infection and Immunity in Children in Uganda

Completed
Conditions
Malaria
First Posted Date
2014-03-21
Last Posted Date
2018-04-05
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
173
Registration Number
NCT02094508
Locations
🇺🇬

Rakai Health Sciences Program Uganda Virus Research Institute, Kalisizo, Uganda

Auranofin PK Following Oral Dose Administration

Phase 1
Completed
Conditions
Amoebiasis
Interventions
First Posted Date
2014-03-17
Last Posted Date
2017-04-28
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
15
Registration Number
NCT02089048
Locations
🇺🇸

Quintiles Phase I Services - Overland Park, Overland Park, Kansas, United States

Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995

Conditions
Granulomatous Disease, Chronic
First Posted Date
2014-03-10
Last Posted Date
2021-09-02
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
1480
Registration Number
NCT02082353
Locations
🇺🇸

University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States

🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

UCLA, Los Angeles, California, United States

and more 41 locations

Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study

Phase 2
Completed
Conditions
Human Immunodeficiency Virus
Interventions
First Posted Date
2014-03-07
Last Posted Date
2020-12-29
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
53
Registration Number
NCT02081638
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

🇺🇸

Hennipen County Medical Center, Minneapolis, Minnesota, United States

Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor

Early Phase 1
Terminated
Conditions
Cancer
Interventions
First Posted Date
2014-02-21
Last Posted Date
2018-07-12
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
2
Registration Number
NCT02069080
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990

Completed
Conditions
Wiskott-Aldrich Syndrome
First Posted Date
2014-02-17
Last Posted Date
2020-08-10
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
305
Registration Number
NCT02064933
Locations
🇺🇸

Nationwide Children's Hospital, Columbus, Ohio, United States

🇺🇸

Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

and more 40 locations

Nitazoxanide Versus Placebo for the Treatment of Hospitalized Subjects With Severe Acute Respiratory Illness

Phase 2
Completed
Conditions
Severe Acute Respiratory Illness
Interventions
Drug: Placebo
First Posted Date
2014-02-07
Last Posted Date
2018-08-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
260
Registration Number
NCT02057757
Locations
🇲🇽

Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosi, Mexico

🇲🇽

Instituto Nacional de Pediatria, Coyoacan, Mexico

🇲🇽

Hospital General Dr. Aurelio Valdivieso, Oaxaca, Mexico

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath